Hôpital Pitié Salpêtrière - AP-HP

98 currently recruiting clinical trials
Create patient profile for matching
Phase 1 Multiple myeloma #NCT05862012
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Monoclonal antibodies Immunomodulator
Excluded previous treatments
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Ichnos Sciences SA
Phase 1 Multiple myeloma #NCT05828511 #2022-500800-24-00
Phase 1 cohorts
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive Radiotherapy
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Regeneron Pharmaceuticals
Phase 1 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06026410
Bras 1 (Tumeurs solides avancées avec altération du gène RAS)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other KRAS HRAS KRAS G12C KRAS G12D KRAS non G12C NRAS
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Kura Oncologie, Inc.
Phase 1 Cervical / Vulvar / Vaginal cancer #NCT05983432 #2023-506539-14-00
Cohorte cancer du col de l'utérus
Required histologic types
Cervical cancer
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
SystImmune Inc.
Phase 1 Stomach and esophageal cancer #NCT05983432 #2023-506539-14-00
Cohorte Cancer de l'oesophage
Required histologic types
Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
SystImmune Inc.
Phase 1 Prostate cancer #NCT05983432 #2023-506539-14-00
Cohorte cancer de la prostate métastatique résistant à la castration
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Chemotherapy
Hôpital Pitié Salpêtrière - AP-HP (Paris)
SystImmune Inc.
Phase 1 Ovarian / Fallopian tubes / Peritoneum cancer #NCT05983432 #2023-506539-14-00
Cohorte adénocarcinome ovarien
Required histologic types
Epithelial ovarian cancer Fallopian tube cancer Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
SystImmune Inc.
Phase 1 Breast cancer #NCT05983432 #2023-506539-14-00
Cohortes cancer du sein
Required HER2 statuses
HER2 Negative HER2 Low
Required HR statuses
HR Negative HR Positive
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Targeted therapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
Phase 1 Endometrial cancer #NCT05983432 #2023-506539-14-00
Cohorte cancer de l'endomètre
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
SystImmune Inc.
Phase 1 Lung cancer #NCT05983432 #2023-506539-14-00
Cohorte CPNPC EGFR muté
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Hôpital Pitié Salpêtrière - AP-HP (Paris)
SystImmune Inc.